883d1c11 Aa54 57c7 E053 2995a90a6151
Anastrozole Tablet, Coated
Product Images NDC 60687-112
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Anastrozole (NDC 60687-112). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Blister
Anastrozole tablets with a strength of 1mg and USP labeling. Lot number and expiration date are present.*
Carton
This is a description of Anastrozole Tablets, USP sold in a pack containing 30 tablets. Each tablet includes Anasirozole and the usual dosage information is not available. The tablets should be stored at temperatures between 20 to 25°C (68" o 77°F) or between 15" 10 50°C (59" {0 86°F) or USP Controlled Room Temperature. The pack should be kept away from children and not be used if the blisters or packaging is damaged. Additionally, the pack includes a patient information sheet with 16 sheets per patient. The manufacturing company is American Health Packaging, Columbus, Ohio. However, since some of the text is incomplete, some important information may be missing.*
Figure 1
This appears to be a chart showing the "Proportion alive and disease-free" for a randomized treatment involving two drugs: tamodfen and tamoten as well as anastrozole. The chart may be depicting the survival rate of patients over time, measured in months. However, the specifics of the chart and the results are difficult to ascertain due to the quality of the text.*
Figure 2
This appears to be a chart or graph displaying the proportion of patients who are alive and disease-free after receiving randomized treatment with two different drugs (anastrozole and amoxifen). The chart also includes information on disease-free survival in months and the number of patients at risk. However, without more context or information it is difficult to provide a more specific or meaningful description.*
Figure 3
This appears to be a graph plotting the percentage of people who remained free of an event over time in months. The graph plots two randomized treatments, Anastrozole and Tamoxifen, with the number of patients at risk decreasing over time. The vertical axis has been truncated to improve clarity. There is no additional information available from the text.*
Figure 4
This is a graph that shows the time to an event (in months) and the proportion of event-free patients for randomized treatment of anastrozole and tamoxifen. The number of patients at risk is also given. Some text on the vertical axis was truncated to improve the clarity of the Kaplan-Meier curves.*
Figure 5
This is a graph displaying the effectiveness of Anastazole versus Tamoxifen for treating a disease over a period of two years, with the x-axis representing the number of months and the y-axis representing the number of patients at risk. The data suggests that the progression rate for Anastazole is lower than for Tamoxifen, as Anastazole patients show slower progression over time.*
Figure 6
This appears to be a graph depicting the time to progression for randomized treatment of anastrozole and tamoxifen. The X-axis shows time in months, while the Y-axis shows the proportion that is not progressing. The graph provides data points for each month up to 40 months, with the number at risk decreasing at each interval.*
Structure
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
